Russian Journal of Oncology

Peer-review bimonthly medical journal.

Editor-in-chief

Journal founders

  • Izdatelstvo "Meditsyna"
  • Eco-Vector Publishing Group

Publisher

About

Since 1996 the journal publishes original articles and reviews that cover current achievements in the fields of clinical and experimental oncology as well as practical aspects of diagnosis and comprehensive treatment of malignant tumors. The journal offers insights into actual experience of cancer centers, discusses the current state of oncology research and practice outside Russia, and facilitates experience exchange. The journal also publishes medical news and material on the implementation of scientific discoveries, the most essential theoretical and practical issues, and the history of oncology.

The journal is aimed at a wide range of medical professionals: oncologists, surgeons, general practitioners, and public health officials focusing on the diagnosis and treatment of cancers.

Types of accepted articles

  • reviews
  • systematic reviews and metaanalyses
  • original research
  • clinical case reports and series
  • letters to the editor
  • short communications

Publications

  • in English and Russian
  • bimonthly, 6 issues per year
  • continuously in Online First
  • with NO Article Processing Charges (APC)
  • distribution in hybrid mode - by subscription and/or Open Access
    (OA articles with the Creative Commons Attribution 4.0 International License (CC BY-NC-ND 4.0))

Indexation

  • Russian Science Citation Index (Web of Science)
  • Russian Science Electronic Library (eLibrary.ru)
  • Google Scholar
  • Ulrich's Periodicals directory
  • WorldCat
  • Crossref

 

Announcements

 
No announcements have been published.
 
More Announcements...

Current Issue

Open Access Open Access  Restricted Access Access granted  Restricted Access Subscription or Fee Access

Vol 26, No 2 (2021)

Cover Page

Full Issue

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Original Study Articles

Phagocytic and chemiluminescent activity of blood neutrophils in patients with bladder cancer
Savchenko A.A., Zukov R.A., Firsov M.A., Slepov E.V., Belenyuk V.D., Gvozdev I.I., Borisov A.G.
Abstract

BACKGROUND: Tumor microenvironment modulates (including with the help of metabolites) the functional activity of the neutrophils that contribute to the reprogramming of the antitumor activity into a protumor one.

AIMS: To study the phagocytic and chemiluminescent activity of neutrophils in patients with bladder cancer (BC) under the influence of metabolites of the tumor microenvironment in vitro.

MATERIALS AND METHODS: We examined 37 patients with superficial BC (T1,а,isN0M0) and considered 32 healthy individuals as a control group. Neutrophils isolated from their blood were incubated in vitro with lactate, ADP, and glutamate. Phagocytic activity was examined using flow cytometry, and the intensity of the respiratory burst of neutrophils was evaluated via chemiluminescent analysis.

RESULTS: In patients with BC, the phagocytic index (PhI) values are reduced compared to the control sample (without in vitro metabolite exposure) and when exposed to glutamate, while the effect of lactate on cells causes an increase in the phagocytic number and PhI. Moreover, under the influence of lactate in vitro, the activity of spontaneous and zymosan-induced chemiluminescence of neutrophils decreases. ADP causes a decrease in spontaneous chemiluminescence only. Finally, under the influence of glutamate, the indicators of spontaneous and induced chemiluminescence decrease.

CONCLUSIONS: Under the influence of lactate and ADP (products of tumor cells), the phagocytic activity of a population of immature neutrophils is stimulated, which leads to myeloid suppressor cells that inhibit antitumor immunity. Thus, metabolites of the tumor microenvironment modulate the activity of the respiratory burst of neutrophils in patients with BC.

Russian Journal of Oncology. 2021;26(2):39-48
pages 39-48 views
Prognostic value of quantitative assessment of macrophage content (CD68+) in the peritumoral zone of clear cell renal cell carcinoma
Bobrov I.P., Lazarev A.F., Cherdantseva T.M., Klimachev I.V., Klimachev V.V., Myadelets M.N., Lepilov A.V., Dolgatov A.Y., Korsikov N.A., Dolgatova E.S., Lushnikova E.L., Bakarev M.A.
Abstract

AIM: To quantitatively analyze the macrophage distribution density (MF) of the peritumoral zone (PZ) of clear cell renal cell carcinoma (CCRCC) and determine the relationship of MF distribution density in PZ with clinical and morphological prognostic variables and postoperative survival of patients.

MATERIALS AND METHODS: The study included 52 patients with CCRCC, who had an average age of 56.7±0.8 years. Using monoclonal mouse antibodies for CD68 (clone PG-M1, DAKO), using an immunohistochemical method, macrophages were identified in the paraffin sections. The average amount of MF in the PZ was determined in three fields of view at ×400 magnification. For the PZ, the tissue was taken directly adjacent to the tumor to the conditionally unchanged kidney tissue.

RESULTS: The correlation analysis revealed that the density of the MF distribution in the CCRCC was interrelated with the stage of the disease (r=0.66; p=0.0001), size of the tumor node (r=0.52; p=0.0001), degree of anaplasia according to Fuhrman (r=0.80; p=0.0001), presence of metastases (r=0.62; 0.0001), and postoperative survival of patients (r=0.53; p=0.0001). However, there were no correlations with the gender (r=0.007; p=0.62) and age of the patients (r=0.03; p=0.83). With the number of MF in the PP <8.8, the cumulative proportion of survivors by the five-year term was 0.70 (70%). Moreover, when the number of MF in the PZ was ≥8.8, none of the patients lived to the five-year term, the cumulative proportion of survivors was 0 (log-rank-test, p=0.000001).

CONCLUSION: The density of MF distribution in PZ is interrelated with significant clinical and morphological parameters of CCRCC and is a predictor of the prognosis of five-year postoperative survival of patients. Thus, quantitative estimation of the number of MF in the PZ can be used in predicting the course of CCRCC along with the traditional classical forecasting factors.

Russian Journal of Oncology. 2021;26(2):49-56
pages 49-56 views

Reviews

The evolution of modern notions about bladder cancer
Yurchenko A.A., Firsov M.A., Zukov R.A., Slepov E.V.
Abstract

The review details the evolution in the researchers’ perspective of bladder cancer over the past five decades. The history of the study, pathogenesis, etiology, and the clinical significance of urinary bladder are briefly discussed. The review presents currently prominent theories regarding the pathogenesis of urinary bladder neoplasms and the foundational research in this field. The article briefly discusses the molecular changes the development of bladder cancer and studies of the urine microbiome during oncogenesis

Russian Journal of Oncology. 2021;26(2):57-64
pages 57-64 views

Editorials

75th Anniversary of Altai oncological service. Current diagnostic and treatment capacities of neoplastic diseases in Altai region
Lazarev A.F., Vikhlyanov I.V.
Abstract

Initiation of oncological services in the Altaiskiy Kray began simultaneously with the creation of the Russian anti-cancer service. It was in that difficult post-war period, when the country was in dire need of population restoration, that the fight against cancer increased by the order of the USSR council “On measures to improve oncological care for the population.” This most crucial historical decision served as a catalyst not only for the technological development of the oncology service but also for the scaling of its key achievements, tools, and algorithms for including the population (prevention, oncology registration, etc.) into the regional oncology network. Thus, in 1946, among the first in the country, an oncology office was opened in post-war Barnaul.

Russian Journal of Oncology. 2021;26(2):65-71
pages 65-71 views


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies